A new type of immunotherapy that directs patients' immune responses toward tumor cell killing, IMCgp100, showed efficacy in some patients with advanced melanoma.
Patients with a variety of hematologic cancers benefited from treatment with OTX015, a member of a new class of investigational epigenetic therapies that block the activity of bromodomain and extraterminal (BET)-bromodomain proteins.
Although the cumulative success rate for new agents for advanced NSCLC is lower than the industry-estimated rate, clinical trial success has been substantially increased by biomarker- and receptor-targeted therapies.
Health-related quality of life assessment in randomized clinical trials in small cell lung cancer provides added information in studies where the treatment arms do not differ in terms of efficacy.
The diabetes drug metformin is undergoing investigation as a potential treatment for different cancers in numerous clinical trials, but results vary.
A phase 1 trial of endoxifen, an active metabolite of the cancer drug tamoxifen, indicates that the experimental drug is safe and provides early evidence for antitumor activity.
The first investigator results from an unprecedented nationwide effort to test promising new breast cancer drugs before the tumor is removed were presented during the 2013 San Antonio Breast Cancer Symposium.
Imetelstat, a novel telomerase-inhibiting drug, has been found to induce morphologic, molecular, and clinical remissions in some patients with myelofibrosis, according to a new study. The results were presented at the 2013 ASH Annual Meeting, in New Orleans.
Adult patients with Burkitt lymphoma had excellent long-term survival rates—upwards of 90%—following treatment with low-intensity chemotherapy regimens, according to a new clinical trial finding.
A research team from the NCI and ASCO presented a summary of best practices and strategies for future research in a co-sponsored symposium.
Recent discoveries about the genetics and cell signaling pathways of thyroid tumors have lead to the development of kinase inhibitors that target tumor cell division and blood vessels.
An investigational drug improved median survival while reducing risk of disease progression or death in persons with metastatic gastric cancer participating in the phase III REGARD trial.
The SHIVA trial is the first randomized trial to look at patient outcomes after treatments were chosen based on individual molecular profiles of each person's tumor.
Clinical trial focusing on bone marrow transplantation and rental transplant for multiple myeloma. Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)
Clinical trial focusing on ACY-1215, bortezomib, and dexamethasone. Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
Clinical trial focusing on cell surface markers and pim kinases. Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma
Clinical trial focusing on genetics and multiple myeloma. Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass)
Clinical trial focusing on TH-302, Dexamethasone, and Bortezomib. Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma
Clinical trial focusing on epidermal micrografts. Use of the Epidermal Micrografts for Wound Healing After Mohs or Excisional Surgery for Skin Cancer
Clinical trial focusing on biomarker analysis for translational integration in colorectal cancer. Assessment of Clinically Related Outcomes and Biomarker Analysis for Translational Integration in Colorectal Cancer (ACROBATICC)
A trial comparing pazopanib and sunitinib found pazopanib to have better safety and health-related quality-of-life profiles among persons with metastatic renal cell carcinoma.
Even in advanced stages, total tumor size can have a major impact on survival in non-small cell lung cancer (NSCLC), according to a new study.
After 18 years of follow-up, the drug finasteride was shown to reduce the risk for prostate cancer by approximately one third, but did not significantly affect overall survival in men or survival after prostate cancer diagnosis.
Changes made 5 years ago to accelerate time-to-initiation of clinical trials sponsored by the National Cancer Institute have paid off in the form of faster activation of studies.
FDA-approved clinical trials progress through three phases: the first shows safety, the second determines efficacy and further evaluates safety, and the third seeks to prove a drug's superiority over existing treatments. But when a drug's benefit is obvious in the first or second phase, is the third, and costly, phase needed?
Results for almost half of U.S. cancer drug trials are still not available three years after study completion.
A newly reported clinical trial used a vaccine that stimulated dendritic cells to treat newly diagnosed advanced melanoma.
Hispanic cancer patients rarely participate in clinical trials, but researchers want to tailor a Spanish-language DVD to change this situation.
A new streamlined method rapidly identifies genetic changes in small protein fragments unique to melanoma cancer cells.
New data has confirmed the biological action of the drug MGN1703 and suggests that it may be possible to identify which patients with gastrointestinal cancer will benefit most from the treatment.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |
